Drug Approval | October 29, 2021
Boehringer Ingelheim announces EMA marketing authorisation for spesolimab
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The NFI is published to promote the rational use of medicines in the country.
Acute therapies continue to report strong growth compared to chronic ones.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Subscribe To Our Newsletter & Stay Updated
